Power law zone | Alprazolam (n = 463,203) | Gabapentin (n = 267,693) | Opioid (n = 2,077,393) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
PLG1 | PLG2 | PLG3 | PLG4 | PLG1 | PLG2 | PLG3 | PLG1 | PLG2 | PLG3 | |||
N of cases | 241,992 | 161,677 | 49,603 | 9931 | 174,989 | 90,590 | 2114 | 1,833,724 | 186,258 | 57,411 | ||
Lorenz-1 in follow-up | 0.0 | 0.0 | 1.6 | 45.3 | 0.0 | 1.4 | 58.5 | 0.0 | 0.5 | 34.5 | ||
Lorenz-1 sensitivity, specificity, PPV, NPVa (%) | 83.5, 98.8, 45.3, 99.8 | 48.9, 99.7, 58.5, 99.5 | 95.4, 98.2, 34.5, 100.0 | |||||||||
Incident Lorenz-1 in follow-up | 0.0 | 0.0 | 1.6 | 20.7 | 0.0 | 1.1 | 0.0 | 0.0 | 0.5 | 9.9 | ||
Incident Lorenz-1 sensitivity, specificity, PPV, NPVa (%) | 69.9, 98.3, 20.7, 99.8 | 0.0, 99.2, 0.0, 99.6 | 85.5, 97.5, 9.9, 100.0 | |||||||||
IPH observation year | 3.5 | 5.0 | 6.6 | 6.3 | 7.0 | 8.7 | 9.5 | 5.7 | 9.3 | 8.4 | ||
IPH follow-up | 3.6 | 5.0 | 6.6 | 7.3 | 6.7 | 8.4 | 9.4 | 4.5 | 8.1 | 8.2 | ||
IPH % change | 2.9 | 0.0 | 0.0 | 15.9 | − 4.3 | − 3.4 | − 1.1 | − 21.1 | − 12.9 | − 2.4 | ||
IPH sensitivity, specificity, PPV, NPV (%) | 3.5, 97.9, 7.3, 95.6 | 1.0, 99.2, 9.4, 92.7 | 4.6, 97.3, 8.2, 95.2 | |||||||||
SUDb IPH observation year | 0.6 | 1.2 | 2.0 | 2.0 | 1.4 | 1.7 | 2.6 | 0.7 | 2.3 | 2.6 | ||
SUDb IPH follow-up | 0.6 | 1.2 | 2.2 | 2.8 | 1.3 | 1.6 | 2.5 | 0.7 | 2.2 | 2.9 | ||
SUDb IPH % change | 0.0 | 0.0 | 10.0 | 40.0 | − 7.1 | − 5.9 | − 3.8 | 0.0 | − 4.3 | 11.5 | ||
SUD IPH sensitivity, specificity, PPV, NPVa (%) | 5.7, 97.9, 2.8, 99.0 | 1.4, 99.2, 2.5, 98.6 | 9.4, 97.3, 2.9, 99.2 |
Utilization quartile | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
N of cases | 133,446 | 108,543 | 103,532 | 117,680 | 71,889 | 60,802 | 65,223 | 69,779 | 486,760 | 537,304 | 528,704 | 524,625 |
Lorenz-1 in follow-up | 0.0 | 0.0 | 0.0 | 4.6 | 0.0 | 0.0 | 0.0 | 3.6 | 0.0 | 0.0 | 0.0 | 4.0 |
Lorenz-1 sensitivity, specificity, PPV, NPVa (%) | 99.5, 75.5, 4.6, 100.0 | 99.6, 74.6, 3.6, 100.0 | 99.9, 75.5, 4.0, 100.0 | |||||||||
Incident Lorenz-1 in follow-up | 0.0 | 0.0 | 0.0 | 2.5 | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 | 0.0 | 0.0 | 1.3 |
Incident Lorenz-1 sensitivity, specificity, PPV, NPVa (%) | 99.2, 75.1, 2.5, 100.0 | 99.1, 74.2, 1.4, 100.0 | 99.7, 75.0, 1.3, 100.0 | |||||||||
IPH observation year | 3.2 | 4.0 | 4.7 | 6.0 | 6.4 | 7.1 | 8.2 | 8.9 | 2.8 | 4.7 | 7.3 | 9.3 |
IPH follow-up | 3.4 | 3.9 | 4.7 | 6.1 | 6.1 | 6.9 | 7.7 | 8.5 | 3.2 | 3.8 | 5.2 | 7.4 |
IPH % change | 6.2 | − 2.5 | 0.0 | 1.7 | − 4.7 | − 2.8 | − 6.1 | − 4.5 | 14.3 | − 19.1 | − 28.8 | − 20.4 |
IPH sensitivity, specificity, PPV, NPVa (%) | 34.6, 75.0, 6.1, 96.1 | 30.5, 74.3, 8.5, 93.1 | 38.0, 75.4, 7.4, 95.9 | |||||||||
SUDb IPH observation year | 0.5 | 0.8 | 1.1 | 1.7 | 1.2 | 1.4 | 1.5 | 1.7 | 0.3 | 0.5 | 0.8 | 1.8 |
SUDb IPH follow-up | 0.5 | 0.8 | 1.1 | 1.9 | 1.2 | 1.3 | 1.4 | 1.7 | 0.4 | 0.5 | 0.7 | 1.8 |
SUDb IPH % change | 0.0 | 0.0 | 0.0 | 11.8 | 0.0 | − 7.1 | − 6.7 | 0.0 | 33.3 | 0.0 | − 12.5 | 0.0 |
SUD IPH sensitivity, specificity, PPV, NPVa (%) | 45.9, 74.8, 1.9, 99.2 | 31.6, 74.0, 1.7, 98.7 | 52.4, 75.0, 1.8, 99.4 |